Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Dual-Targeting CAR-T therapy shows promise for tough lymphoma

NCT ID NCT05421663

Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This study tests a new treatment called prizloncabtagene autoleucel (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The goal is to control the disease and improve response rates.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

166 people

The number who actually took part.

Started

Aug 2022

Expected to finish

Jul 2041

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive * Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL), Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma; Received at least 2 prior lines of systemic therapy; Relapsed or refractory disease defined as 1 or more of the following: Stable disease or Progressive disease (PD) as best response to most recent anti-lymphoma therapy OR disease progression or recurrence after a partial response (PR) or complete response (CR) to most recent anti lymphoma therapy; cohort specific requirements as mentioned in protocol * Measurable disease as defined by Lugano 2014 classification * Eastern cooperative oncology group (ECOG) performance status of 0 to 2 Exclusion Criteria: * History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed) * History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis * History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder * Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system * Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones) * Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection * Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell/histiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia * Any prior solid organ or allogeneic stem cell transplantation * Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Follicular large B-cell lymphoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma diffuse large B-cell lymphoma follicular lymphoma large B-cell lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma Richter transformation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphoma, B-cell Lymphoma, large B-cell, diffuse Lymphoma, non-Hodgkin

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, 05505, South Korea

  • Calvary Mater Newcastle Hospital

    Waratah, 2298, Australia

  • City of Hope

    Duarte, California, 91010, United States

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Erasmus MC

    Rotterdam, 3015 GD, Netherlands

  • Fiona Stanley Hospital

    Murdoch, 6150, Australia

  • Greco Hainesworth Tennessee Oncology Centers for Research

    Nashville, Tennessee, 37203, United States

  • Hosp Clinic de Barcelona

    Barcelona, 08036, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp Univ Vall D Hebron

    Barcelona, 08035, Spain

  • ICO L'Hospitalet - Hospital Duran i Reynals

    Barcelona, 08908, Spain

  • Levine Cancer Institute

    Charlotte, North Carolina, 28001, United States

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Odense University Hospital

    Odense, 5000, Denmark

  • Princess Margaret Cancer Centre University Health Network

    Toronto, Ontario, M5G2M9, Canada

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Rutgers Cancer Institute of New Jersey

    Piscataway, New Jersey, 08854, United States

  • Samsung Medical Center

    Seoul, 06351, South Korea

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • Seoul National University Hospital

    Seoul, 03080, South Korea

  • St Vincents Hospital Melbourne

    Fitzroy, 3065, Australia

  • St. David's South Austin Medical Center

    Austin, Texas, 78704, United States

  • Swedish Cancer Institute

    Seattle, Washington, 98104, United States

  • Texas Transplant Institute

    San Antonio, Texas, 78229, United States

  • The Alfred Hospital

    Melbourne, 3004, Australia

  • The Christie NHS Foundation Trust Christie Hospital

    Manchester, M20 4BX, United Kingdom

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • University College London Hospitals

    London, NW1 2BU, United Kingdom

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio, 44106, United States

  • University of Iowa Hospital and Clinics

    Iowa City, Iowa, 52242, United States

  • University of Kentucky Medical Center

    Lexington, Kentucky, 40536, United States

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.